Program
ramantamig
Also written as “JNJ-79635322” and “Ramantamig”.
Its studies are mostly in Multiple Myeloma, led by Johnson & Johnson.
Furthest: phase 3, since Nov 21, 20257 company-led studies, 7 open or runningNext primary completion: Apr 19, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 77 open or running | phase 3since Nov 21, 2025 | Dec 7, 2022 | Apr 19, 2027phase 1 · NCT05652335 |
- Named in Johnson & Johnson’s own pipeline as
ramantamig
, phase 3, as of Oct 13, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 7, 2022First study: phase 1 study in RecurrenceFirst studyNCT05652335 · 180 planned · United States, Belgium, France and more
- Jul 8, 2024Phase 2 study in Multiple MyelomaNCT06500884 · 210 planned · United States, Brazil, Netherlands and more
- Nov 21, 2025Phase 3 study in Multiple MyelomaPhase 3 reachedNCT07258511 · 400 planned · United States, Australia, Brazil and more
- Nov 25, 2025Phase 2 study in Multiple MyelomaNCT07266441 · 168 enrolled · United States, China, Israel and more
- Apr 1, 2026Phase 3 study in Multiple MyelomaNCT07518186 · 700 planned · United States, Australia, Brazil and more
- Jun 18, 2026Phase 3 study in Multiple MyelomaNCT07665450 · 1,000 planned · Australia, Czechia, France and more
- Oct 23, 2026Phase 3 study in Multiple MyelomaNCT07903272 · 1,000 planned
Ahead
- Apr 19, 2027Primary completion: phase 1 study in RecurrenceNCT05652335
- Jun 14, 2027Primary completion: phase 2 study in Multiple MyelomaNCT07266441
- Dec 12, 2028Primary completion: phase 3 study in Multiple MyelomaNCT07258511
- Apr 29, 2029Primary completion: phase 3 study in Multiple MyelomaNCT07518186
TargetBeta
“A T-cell engager and trispecific antibody targeting the two tumor-associated antigens (TAAs) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and human G-protein coupled receptor family C group 5 member D (GPRC5D), and the T-cell surface antig…”NCIt, read by Claude
“A T-cell engager and trispecific antibody targeting the two tumor-associated antigens (TAAs) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and human G-protein coupled receptor family C group 5 member D (GPRC5D), and the T-cell surface antigen ”NCIt, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003rule | Innovent Biologics | phase 3 | 4 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07903272Multiple Myeloma | 3 | Not yet recruiting | Jan 11, 2037 | 1,000 |
| NCT07665450Multiple Myeloma · Australia, Czechia, France and more | 3 | Recruiting | Sep 4, 2030 | 1,000 |
| NCT07518186Multiple Myeloma · United States, Australia, Brazil and more | 3 | Recruiting | Apr 29, 2029 | 700 |
| NCT07266441Multiple Myeloma · United States, China, Israel and more | 2 | Active, not recruiting | Jun 14, 2027 | 168 |
| NCT07258511Multiple Myeloma · United States, Australia, Brazil and more | 3 | Recruiting | Dec 12, 2028 | 400 |
| NCT06500884Multiple Myeloma · United States, Brazil, Netherlands and more | 2 | Recruiting | May 30, 2030 | 210 |
| NCT05652335Recurrence · United States, Belgium, France and more | 1 | Recruiting | Apr 19, 2027 | 180 |
How it is read
Names in the registry
- “JNJ-79635322”, 4 entries
- “Ramantamig”, 3 entries
Conditions, from the studies’ own filings
- Multiple Myeloma, 7 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.